INZY

Analyst Ratings: Tazeen Ahmad from Bank of America Securities maintains a Buy rating on Inozyme Pharma with a price target of $11.00, while the analyst consensus suggests a Strong Buy with a higher target of $13.57, indicating significant upside potential.

Financial Performance: Inozyme Pharma reported a GAAP net loss of $27.07 million for the last quarter, compared to a revenue of $1.98 million and a net loss of $21.54 million in the previous year.

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

Analyst Rating Update: Piper Sandler analyst Allison Bratzel has lowered Inozyme's price target from $30 to $23 while maintaining an Overweight rating, citing the company's ongoing execution despite a 75% decline in shares over the past year.

Strategic Developments: Inozyme is focusing on its ENPP1 Deficiency program and has extended its cash runway to Q1 2026, which the firm views as a positive risk/reward scenario for investors.

Analyst Rating: Marc Frahm from TD Cowen maintains a Buy rating on Inozyme Pharma, with the stock currently priced at $1.14 and an analyst consensus of Strong Buy, targeting a price of $19.50.

Market Performance: Inozyme Pharma has experienced a one-year high of $7.80 and a low of $1.04, with an average trading volume of 734.6K shares.

Financial Overview and Strategic Changes: Inozyme Pharma reported a net loss of $102 million for 2024, with cash reserves expected to support operations until early 2026. The company is implementing a 25% workforce reduction to focus resources on its ENPP1 Deficiency program.

Clinical Trial Updates: Enrollment in the ENERGY 3 pivotal trial for INZ-701 in pediatric patients with ENPP1 Deficiency has been completed, with topline data anticipated in early 2026. Positive interim results from related trials indicate improvements in disease measures among treated infants and children.

Company's Strategic Review: The Company is focusing on filing a Biologics License Application for INZ-701 to treat ENPP1 Deficiency, while postponing future trials for ABCC6 Deficiency and calciphylaxis. A workforce reduction of about 25% has been implemented to extend the cash runway into early 2026.

CEO's Statement: CEO Douglas Treco emphasized the necessity of these difficult decisions to maximize the potential of advancing INZ-701, expressing gratitude towards the team members for their dedication and contributions to the mission.

Company Financial Status: As of December 31, 2024, the company has $113.1 million in cash and short-term investments, which is expected to cover its cash flow needs until early 2026.

Stock Ratings Update: Inozyme's FY24 EPS was reported at ($1.62), with varying price target adjustments from analysts, including a decrease by Piper Sandler and Wells Fargo, and an increase by H.C. Wainwright.

Inozyme's Progress: Inozyme (INZY) has made significant advancements in its ENPP1 Deficiency program, completing enrollment in the pivotal ENERGY 3 trial and reporting promising interim data for infants and young children.

Stock Ratings Update: Analysts have adjusted their price targets for Inozyme, with some lowering it significantly while others have raised it, reflecting mixed sentiments on the company's stock performance.

Company Presentation Announcement: Inozyme Pharma, Inc. will have its CEO Doug Treco present at the TD Cowen 45th Annual Health Care Conference on March 3, 2025, with a live webcast available on their website.

About Inozyme Pharma: The company focuses on developing therapies for rare diseases affecting bone health and blood vessel function, with their lead candidate INZ-701 aimed at treating conditions caused by deficiencies in the PPi-Adenosine Pathway.

Inozyme Pharma Presentation: Inozyme Pharma announced that Dr. Kurt Gunter will present data on their enzyme replacement therapy, INZ-701, for ENPP1 Deficiency at the CHOP Cardiology Annual Meeting from February 19-23, 2025.

About ENPP1 Deficiency and Inozyme Pharma: ENPP1 Deficiency is a rare, severe disease affecting bone health and blood vessels with no approved therapies currently available. Inozyme Pharma focuses on developing treatments targeting the PPi-Adenosine Pathway to address this and other related conditions.

Price Target Adjustment: Wells Fargo analyst Tiago Fauth has reduced Inozyme's price target from $14 to $11 while maintaining an Overweight rating, citing supportive infant data and a focus on the ENERGY-3 trial's runway and visibility.

Trial Design Insights: The alignment of the ABCC6 trial design is viewed positively, but it may take a secondary role due to resource allocation, with limited implications for ADA impact expected.

Analyst Ratings: Bank of America Securities analyst Tazeen Ahmad has maintained a Buy rating on Inozyme Pharma (INZY) with a price target of $13, citing the company's promising pipeline and significant progress in clinical trials, particularly the ENPP1 phase 3 trial expected to yield results in early 2026.

Company Overview: Inozyme Pharma focuses on developing therapies for rare genetic diseases related to mineralization deficiencies, with its lead product candidate INZ-701 showing encouraging interim results in trials aimed at improving survival rates and health markers in affected infants.

Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders make informed decisions in the stock market.

Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and timely updates.

Positive Clinical Results: Interim results from Inozyme Pharma's ENERGY 1 trial showed significant improvements in infants and young children with ENPP1 Deficiency, including increased survival rates, reduced arterial calcifications, improved heart function, and no evidence of rickets.

Ongoing Trials and Regulatory Support: Enrollment is complete for the ENERGY 3 pivotal trial, with dosing expected to finish by January 2026, while regulatory guidance has been received for the ASPIRE trial targeting ABCC6 Deficiency in pediatric patients.

Company Presentation Announcements: Inozyme Pharma's CEO, Doug Treco, will present at the Stifel 2024 Healthcare Conference on November 18 and the Jefferies London Healthcare Conference on November 20, with live webcasts available on their website.

About Inozyme Pharma: The company focuses on developing therapies for rare diseases affecting bone health and blood vessel function, with its lead candidate, INZ-701, targeting deficiencies in the PPi-Adenosine Pathway to treat conditions like ENPP1 Deficiency and calciphylaxis.

Real-time Intelligence: Benzinga Pro offers traders the fastest and most accurate stock market intelligence, helping them make informed decisions daily.

Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and alerts generated by Benzinga reporters.

Clinical Trials and Data: Inozyme Pharma is advancing its clinical programs for INZ-701, with interim data from the ENERGY 1 trial expected by the end of 2024 and topline data from the ENERGY 3 pivotal trial anticipated in early 2026. The company plans to initiate registrational trials for calciphylaxis and ABCC6 Deficiency in 2025, pending regulatory approval and funding.

Financial Overview: As of September 30, 2024, Inozyme reported $131.6 million in cash and investments, which is projected to sustain operations into the fourth quarter of 2025. The company experienced a net loss of $24.6 million for the third quarter of 2024, reflecting increased research and development expenses compared to the previous year.

Earnings Report: Inozyme Pharma reported a Q3 GAAP EPS of -$0.39, which is $0.05 better than expected.

Financial Outlook: The company's cash and short-term investments as of September 30, 2024, are projected to sustain operations through the fourth quarter of 2025.